You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Rapid, Portable Test to Monitor Gradual Vision Loss in Dry Age-Related Macular
SBC: ADAPTIVE SENSORY TECHNOLOGY, LLC Topic: NEIDESCRIPTION (provided by applicant): The worldwide demographic trends of aging and obesity will increase the global incidence of blinding eye diseases, which impose significant psychosocial and economic burdens. The leading cause of blindness in the developed world is Age-related Macular Degeneration (AMD), which causes the progressive loss of central vision. Because dry AMD, which exhibits gradua ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Sterculic Acid Analogs to Inhibit Macular Degeneration
SBC: L2 DIAGNOSTICS LLC Topic: NEIABSTRACT The long-term product goal of this project is a small molecule therapeutic for choroidal neovascularization (CNV, the hallmark of wet age-related macular degradation), an abnormal growth of blood vessels in the choroid layer of the eye that results in damage to the retina and consequent blindness. Our lead compound is the natural product sterculic acid, which has been shown to inhibit ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A novel prodrug for K+-ATP channel activation in the glaucomatous eye
SBC: RADIKAL THERAPEUTICS, INC. Topic: NEIDESCRIPTION (provided by applicant): Radikal Therapeutics (RTX) is developing a revolutionary bifunctional small molecule (R-801) for topical therapy of primary open angle glaucoma (POAG). R-801 is constructed from the covalent fusion of 2 chemical domains, each with demonstrated tissue protective properties: 1) a mito-K+-ATP channel activating moiety derived from the isoform non-selective K+-ATP ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
High throughput camelid antibody screening as drug discovery platform
SBC: ABZYME THERAPEUTICS LLC Topic: NIGMSDESCRIPTION (provided by applicant): Monoclonal antibodies are used for treatment of a wide range of diseases from cancer to infectious diseases. However, development of antibodies with high affinity and specificity is still time-consuming, labor-intensiveand unpredictable. Abzyme Therapeutics LLC is actively developing animal-free antibody discovery platforms to accelerate generation of therapeut ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Novel Cell-based Real Time Platform for GPCR Drug Discovery
SBC: LUCIGEN CORPORATION Topic: NIGMSAbstract High throughput screening assays for GPCR drug discovery are hampered by the complex instrumentation associated with current technologies, and the high risk of false-positives and off- target effects. The majority of currently available GPCR drugscreening assays are end-point assays that rely on secondary reporters of GPCR signaling events after signaling has occurred. These assays are fu ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
An In Vitro Human Small Intestine Tissue Model for Drug Permeation Studies
SBC: Mattek Corporation Topic: NIGMSDESCRIPTION (provided by applicant): The perioral route for drug administration remains the most convenient way of clinical therapy and is preferred by patients, however, good bioavailability is a necessary characteristic of new candidate therapeutics. A key parameter for determining oral bioavailability is drug transport and permeability across the small intestine (SI) epithelium. Therefore, in ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Metalloproteinase Inhibitor For Pain and Morphine Tolerance Due To Thermal Injury
SBC: AQUILUS PHARMACEUTICALS INC Topic: NIGMSDESCRIPTION (provided by applicant): Aquilus Pharmaceuticals, Inc. proposes to evaluate the effects of a proprietary matrix metalloproteinase (MMP) inhibitor, AQU-010, for blocking neuropathic pain and morphine tolerance in a thermal injury (TI) rat model.The goals for Phase I are to scale-up the synthesis of AQU-010, determine its oral pharmacokinetics (PK) and target tissue penetration and then ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of a fluorescence liposomal ABCG2 Multidrug Transporter assay
SBC: GLSynthesis Inc. Topic: NIGMSABSTRACT In this project we propose to exploit the recent successful isolation and reconstitution of the important ATP- dependent drug efflux transporter, ABCG2 (BCRP, Breast Cancer Resistance Protein), and combine it with a new transport assay system, the Fluorosome platform, to characterize the interaction of ABCG2 with drugs and drug candidates. The result will provide a useful, novel, highly ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
SELF-NEUTRALIZING OLIGONUCLEOTIDES WITH ENHANCED CELLULAR UPTAKE
SBC: ZATA PHARMACEUTICALS, INC. Topic: NIGMSDESCRIPTION (provided by applicant): There is enormous potential of oligonucleotides (ON) as therapeutics, but the challenge remains how to effectively deliver ON into cells. Currently, there are no effective and reliable ways of delivery. Outer cell membranes resist the cellular uptake of charged ON, and charges-eliminating backbone modifications such as those in peptide nucleic acids (PNA) and m ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
An efficient directed cell migration assay
SBC: Platypus Technologies, LLC Topic: NIGMSProject Summary The goal of this SBIR project is to design and develop an efficient, automation- compatible Directed Cell Migration (DCM) 96-well Assay that distinguishes chemokinetic from chemotactic behavior. Cell migration is currently assayed using trans-membrane well inserts, microfluidic systems and various versions of scratch assays. These methods are expensive and provide inconsistent dat ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health